2-Iodo-1,3-dimethylbenzene | CAS:608-28-6

We serve 2-Iodo-1,3-dimethylbenzene CAS:608-28-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Iodo-1,3-dimethylbenzene

Chemical Name:2-Iodo-1,3-dimethylbenzene
CAS.NO:608-28-6
Synonyms:2-Iodo-1,3-dimethylbenzene
2,6-dimethyl iodobenzene
1,3-dimethyl-2-iodobenzene
1-iodo-2,6-dimethylbenzene
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 227.5±9.0 °C at 760 mmHg
Molecular Formula C8H9I
Molecular Weight 232.061
Flash Point 98.1±7.7 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.593
 
Specification:
Appearance:Pink-brown to red transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2-Iodo-1,3-dimethylbenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-iodo-2,6-dimethylbenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Iodo-1,3-dimethylbenzene Use and application,1-iodo-2,6-dimethylbenzene technical grade,usp/ep/jp grade.


Related News: The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.Cyclopropyl-2-fluoro benzyl ketone manufacturer The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.1,2,4-trichlorobenzene supplier The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.5-Chloro-6-methoxynicotinic acid vendor The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).